Lipoprotein(a) in Cardiovascular Disease: Integrating Epidemiology, Clinical Guidelines, Molar Measurement, and Emerging Therapies.

BACKGROUND: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD = myocardial infarction, ischemic stroke, peripheral artery disease) and aortic valve stenosis. Plasma concentrations of Lp(a) are >90% genetically determined. Multiple drugs in development reduce lipoprotein(a) by 80% to 98%. While the recently announced topline results, the phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular endpoint despite lowering Lp(a), and 3 other cardiovascular outcomes trials remain ongoing. Lipoprotein(a) testing is currently increasing rapidly in many countries. CONTENT: Most guidelines on dyslipidemia and prevention of cardiovascular disease worldwide now advise that Lp(a) should be measured once in all adults, ideally jointly with the first lipid profile ordered. If previous lipid profiles were taken, then Lp(a) should be included in the next lipid profile. Lipoprotein(a) should ideally be measured in nmol/L, and repeat measurements are relevant if drugs are given to lower Lp(a) concentrations, initially at suspected acute coronary syndrome or stroke and again after 1 month, and sometimes in women after menopause. Measuring Lp(a) levels alongside a standard lipid profile provides a more comprehensive initial assessment of a patient's overall cardiovascular risk. Clinical chemistry laboratories that measure lipid profiles should therefore also offer Lp(a) testing. This is easily done as Lp(a) assays can be run on most major clinical chemistry platforms. High Lp(a) is >105 nmol/L (>50 mg/dL). SUMMARY: As use of Lp(a) testing is increasing rapidly worldwide, more clinical chemistry laboratories will likely offer this test locally. Measuring Lp(a) levels alongside a standard lipid profile provides a more comprehensive initial lipid assessment of a patient's cardiovascular risk.

Authors

Institutions

Publication Details

Journal
PubMed
Published
2026-11-13
DOI
https://doi.org/10.1093/clinchem/hvag154
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Lipoprotein(a) in Cardiovascular Disease: Integrating Epidemiology, Clinical Guidelines, Molar Measurement, and Emerging Therapies.

Florian Kronenberg, Signe Vedel‐Krogh, Børge Grønne Nordestgaard, Peter E Thomas
2 links
PubMed
Lipoproteins and Cardiovascular Health
article

Lipoprotein(a) in Cardiovascular Disease: Integrating Epidemiology, Clinical Guidelines, Molar Measurement, and Emerging Therapies.

Florian Kronenberg, Signe Vedel‐Krogh, Børge Grønne Nordestgaard, Peter E Thomas
article en

Abstract

BACKGROUND: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD = myocardial infarction, ischemic stroke, peripheral artery disease) and aortic valve stenosis. Plasma concentrations of Lp(a) are >90% genetically determined. Multiple drugs in development reduce lipoprotein(a) by 80% to 98%. While the recently announced topline results, the phase 3 Lp(a)HORIZON trial of pelacarsen did not meet its primary cardiovascular endpoint despite lowering Lp(a), and 3 other cardiovascular outcomes trials remain ongoing. Lipoprotein(a) testing is currently increasing rapidly in many countries. CONTENT: Most guidelines on dyslipidemia and prevention of cardiovascular disease worldwide now advise that Lp(a) should be measured once in all adults, ideally jointly with the first lipid profile ordered. If previous lipid profiles were taken, then Lp(a) should be included in the next lipid profile. Lipoprotein(a) should ideally be measured in nmol/L, and repeat measurements are relevant if drugs are given to lower Lp(a) concentrations, initially at suspected acute coronary syndrome or stroke and again after 1 month, and sometimes in women after menopause. Measuring Lp(a) levels alongside a standard lipid profile provides a more comprehensive initial assessment of a patient's overall cardiovascular risk. Clinical chemistry laboratories that measure lipid profiles should therefore also offer Lp(a) testing. This is easily done as Lp(a) assays can be run on most major clinical chemistry platforms. High Lp(a) is >105 nmol/L (>50 mg/dL). SUMMARY: As use of Lp(a) testing is increasing rapidly worldwide, more clinical chemistry laboratories will likely offer this test locally. Measuring Lp(a) levels alongside a standard lipid profile provides a more comprehensive initial lipid assessment of a patient's cardiovascular risk.

PubMed
University of Copenhagen (DK), Innsbruck Medical University (AT), Universität Innsbruck (AT), Herlev Hospital (DK), Copenhagen University Hospital (DK), Gentofte Hospital (DK)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon